Victoria Socha

DocwireNews

The preferred method for vascular access in patients requiring hemodialysis is arteriovenous fistula (AVF). AVF failure is associated with increased use of catheter access, and the related increase in morbidity and mortality. According to Mohamad Anas Hussain, MD, PhD, and colleagues, there is a need for an alternative option for vascular access that provides the benefits of AVFs, such as low infection rate, while reducing the associated maturation failure possibility.
During an oral session at ASN Kidney Week 2024, the researchers presented results of a phase 3 trial assessing the safety and efficacy of an acellular tissue engineered vessel (ATEV) compared to autologous AVF. (CLN-PRO-V007; ClinicalTrials.gov, NCT03183245). The presentation was titled Prospective Randomized Trial of Humacyte’s Acellular Tissue Engineered Vessel vs Autologous Arteriovenous Fistula for Hemodialysis Access.
The phase 3, prospective, multicenter, two-arm, randomized controlled trial included 242 individuals undergoing surgical vascular access creation for hemodialysis. Participants were randomized to receive either the ATEV (n=123) or autologous AVF (n=119). Primary outcomes of interest included 6-month functional patency and 12-month secondary patency following access creation. Secondary outcomes were comparisons of access usability and infection rates.
The mean age of the overall cohort was 58.6 years and 29% were female. Participants in the ATEV group had higher rates of functional patency at both six months (81% vs 68% for AVF) and 12 months (68% vs 62% for AVF), P=.0071; joint test for the coprimary endpoints. The mean duration of ATEV use was significantly higher than duration of AVF use (7.5 months vs 6.1 months, respectively; P=.0162).
In the subgroup of female participants, the rates of 6-month functional patency were higher among ATEV users compared to those with AVF access (89% vs 55%, respectively), as were 12-month functional patency rates (81% vs 49%, respectively); P&lt;.001; joint test).
Infection rates related to the access type were comparable (5.8% ATEV vs 4.1% AVF). No unexpected safety events were observed.
“Humacyte ATEV had better access functional patency and usability versus AVFs at one year,” the authors said. “Female subjects experienced improved outcomes, supporting ATEV consideration as a novel access option for subjects at high risk for AVF non-maturation.”
Source: Hussain MA, Ozaki CK, Moore EE, Khondker Z, Parikh SJ, Niklason, LE. Prospective randomized trial of Humacyte’s acellular tissue engineered vessel vs autologous arteriovenous fistula for hemodialysis access. SA-OR95. Abstract of an oral presentation at the American Society of Nephrology Kidney Week 2024; October 26, 2024; San Diego, California. Funding was provided by Humacyte Global, Inc.

Emily Menendez

Meta-Analysis Links High NLR to Reduced OS, PFS in Gastric Cancer

Gastric Cancer

Nivolumab Plus Entinostat Provide Gateway for Future PDAC Treatments

Pancreatic Cancer

Jordana Jampel

RSV Vaccine Effective in Preventing Hospitalization: Retrospective Analysis

Latest News

Comparing Functional Patency of Acellular Tissue Engineered Vessel With AVF

ASN Kidney Week 2024

A trial found that an acellular tissue engineered vessel (ATEV) had better functional patency and usability compared to autologous arteriovenous fistula (AVF) for hemodialysis.

Comparing Functional Patency of Acellular Tissue Engineered Vessel With AVF 

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

GEP-NETs

GIST

Liver Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe